Ionis Pharmaceuticals
pelacarsen
Lp(a)-CVD
Resolved
7days ago
Phase 3 readout Β· ~ Jun 30, 2026 estimated
What's at stake
Phase 3 trial results for pelacarsen in Lp(a)-CVD are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
Β· SEC 8-K
verified 12h ago
βResults from Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen, an Ionis-discovered investigational medicine for lipoprotein(a) (Lp(a))-driven cardiovascular disease (CVD) (Novartis) o Results expected in H1 2026β